CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity

Haematologica

Volumn 90, Issue 5, 2005, Pages 706-707

  Bataille, Régis ^a,c   Robillard, Nelly ^a   Avet Loiseau, Hervé ^a   Hamusseau, Jean Luc ^b   Moreau, Philippe ^b,d  

^a INSTITUT DE BIOLOGIE   (France)

^b HÔTEL DIEU   (France)

^c Laboratory of Hematology   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

14q32; CD221; IGF 1R; Myeloma

Indexed keywords

SOMATOMEDIN C RECEPTOR;

ARTICLE; CHROMOSOME 14Q; CHROMOSOME TRANSLOCATION 14; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DISEASE SEVERITY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PHENOTYPE; PROGNOSIS;

BONE MARROW; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 4; HUMANS; LIFE TABLES; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PLASMA CELLS; PROGNOSIS; RECEPTOR, IGF TYPE 1; SURVIVAL ANALYSIS; TONSIL; TRANSLOCATION, GENETIC;

EID: 20344393906     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Freund GG, Kulas DT, Mooney RA. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI8226. J Immunology 1993;151:1811-20.
2. Georgii-Hemming P, Jernberg Wiklund H, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996;88: 2250-58.
3. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival of proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000;111:626-34.
4. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-1 act as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 1999;93:235-41.
5. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000;96:2856-61.
6. Mitsiades CS, Mitsiades N, Poulaki V, Scholossman R, Akiyama M, Chauhan D, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673-83.
7. Harousseau JL, Shaughnessy J Jr, Richardson P. Multiple myeloma. Hematology 2004:237-56.
8. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for non malignant human plasmablasts. Blood 2001;97:1817-22.
9. Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, et al. The expression of CD20 is aberrant, significantly associated with a small mature plasma-cell morphology, t(11;14) and good survival in multiple myeloma. Blood 2003;102:1070-1.
10. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive therapy. Blood 2002;100:1579-83.
11. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure Akiyama M, Hideshima T, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30.